#	Pagina
attuale pagina	/open-h2020/projects/227112/index.html
-1	/open-h2020/projects/222978/index.html

Opendata, web and dolomites

NATURE-ETN SIGNED

Nucleic Acids for Future Gene Editing, Immunotherapy and Epigenetic Sequence Modification

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

NATURE-ETN project word cloud

Explore the words cloud of the NATURE-ETN project. It provides you a very rough idea of what is the project "NATURE-ETN" about.

regarding nas world despite stage limitations epigenetic intersectoral mutations unrivalled immunotherapies biotech therapy breakthrough therapies outstanding engineering leaders cas9 treatment applicability dna discoveries tech quality immunotherapy meet disruptive environment manipulation cancer originating chemistry industry training laboratories outcomes translation receive workshops predicted materials therapeutic nucleic serious generation na crystallography nature fellows biomaterials scientific questions yield leverage transferable human expertise culture 21st century off business 15 skills give cells smes pioneering editing crispr excellence commercial combined undesired etn acid biologists cell prolonged deletions insertions disease sequencing grow genomics basic base extend tools skillset disciplinary deep gene today paradigm medicine boundaries functioning combination career planning technologies chemists

Project "NATURE-ETN" data sheet

The following table provides information about the project.

Coordinator	DUBLIN CITY UNIVERSITY Organization address address: Glasnevin city: DUBLIN postcode: 9 website: www.dcu.ie contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Ireland [IE]
Total cost	4˙041˙816 €
EC max contribution	4˙041˙816 € (100%)
Programme	1. H2020-EU.1.3.1. (Fostering new skills by means of excellent initial training of researchers)
Code Call	H2020-MSCA-ITN-2019
Funding Scheme	MSCA-ITN-ETN
Starting year	2020
Duration (year-month-day)	from 2020-04-01 to 2024-03-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	DUBLIN CITY UNIVERSITY DUBLIN CITY UNIVERSITY Organization address address: Glasnevin city: DUBLIN postcode: 9 website: www.dcu.ie contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IE (DUBLIN)	coordinator	824˙052.00
2	THE UNIVERSITY OF READING THE UNIVERSITY OF READING Organization address address: WHITEKNIGHTS CAMPUS WHITEKNIGHTS HOUSE city: READING postcode: RG6 6AH website: http://www.rdg.ac.uk contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (READING)	participant	606˙345.00
3	LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN Organization address address: GESCHWISTER SCHOLL PLATZ 1 city: MUENCHEN postcode: 80539 website: www.uni-muenchen.de contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (MUENCHEN)	participant	505˙576.00
4	USTAV ORGANICKE CHEMIE A BIOCHEMIE, AV CR, V.V.I. USTAV ORGANICKE CHEMIE A BIOCHEMIE, AV CR, V.V.I. Organization address address: FLEMINGOVO NAM. 542/2 city: PRAHA 6 postcode: 16610 website: www.uochb.cas.cz contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	CZ (PRAHA 6)	participant	469˙743.00
5	ATDBIO LIMITED ATDBIO LIMITED Organization address address: THE SQUARE FAWLEY city: SOUTHAMPTON HAMPSHIRE postcode: SO45 1DD website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (SOUTHAMPTON HAMPSHIRE)	participant	303˙172.00
6	THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD Organization address address: WELLINGTON SQUARE UNIVERSITY OFFICES city: OXFORD postcode: OX1 2JD website: www.ox.ac.uk contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (OXFORD)	participant	303˙172.00
7	ECOLE NATIONALE SUPERIEURE DE CHIMIE DE PARIS ECOLE NATIONALE SUPERIEURE DE CHIMIE DE PARIS Organization address address: 11 RUE PIERRE ET MARIE CURIE city: PARIS CEDEX 05 postcode: 75231 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (PARIS CEDEX 05)	participant	274˙802.00
8	NATIONAL INSTITUTE FOR BIOPROCESSING RESEARCH AND TRAINING LIMITED NATIONAL INSTITUTE FOR BIOPROCESSING RESEARCH AND TRAINING LIMITED Organization address address: FOSTERS AVENUE MOUNT MERRION city: BLACKROCK DUBLIN postcode: 4 website: www.nibrt.ie contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IE (BLACKROCK DUBLIN)	participant	274˙684.00
9	BASECLICK GMBH BASECLICK GMBH Organization address address: FLORIANSBOGEN 2-4 city: NEURIED postcode: 82061 website: www.baseclick.eu contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (NEURIED)	participant	252˙788.00
10	UNIWERSYTET WARSZAWSKI UNIWERSYTET WARSZAWSKI Organization address address: KRAKOWSKIE PRZEDMIESCIE 26/28 city: WARSZAWA postcode: 00 927 website: www.uw.edu.pl contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	PL (WARSZAWA)	participant	227˙478.00

Map

Project objective

Nucleic acid (NAs) therapies are predicted to yield major advances in the treatment of human disease and new approaches in NA design are required to extend the boundaries of today`s gene editing technologies, cancer immunotherapies, and epigenetic base manipulation tools. Current gene editing technologies involving CRISPR-Cas9, despite their wide applicability, have serious limitations involving off-target or prolonged effects that produce mutations, insertions, and deletions leading to undesired therapeutic outcomes. Questions also remain regarding the development and delivery of NAs for manipulation of T-cells, now seen as the new paradigm in cancer research. NATURE-ETN will meet this challenge by engineering new biomaterials and therapies to extend the boundaries of i.) gene editing technology, ii.) cancer immunotherapy, and iii.) epigenetic base manipulation. Our research programme involves world-leading chemists and biologists in combination with high-tech/biotech SMEs and industry partners. We will use our combined expertise in NA chemistry, DNA crystallography, materials chemistry, cell culture, and epigenetic sequencing to develop an outstanding multi-disciplinary environment were 15 Early Stage Researchers will receive unrivalled research training in the most exciting gene therapy research today. The intersectoral training provided will encompass scientific and transferable skills, an understanding of industry, and features targeted workshops in sequencing and genomics along with quality/business management and future career planning. NATURE-ETN will leverage breakthrough discoveries—some originating from our own laboratories—to provide training excellence to give our fellows a deep skillset in the translation of basic research into high functioning commercial NA biomaterials. NATURE-ETN will develop the next generation of pioneering scientific leaders in Europe where they will grow our commercial need for disruptive technologies in 21st century medicine.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NATURE-ETN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NATURE-ETN" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.1.)

ORBITAL (2019)

Ocular Research By Integrated Training And Learning

Read More

MLFPM2018 (2019)

Machine Learning Frontiers in Precision Medicine

Read More

INSPIRE (2020)

INnovation in Safety Pharmacology for Integrated cardiovascular safety assessment to REduce adverse events and late stage drug attrition.

Read More